Clinical Trials Browser

Lung Neoplasms

Triple Negative Breast Neoplasms

Glioblastoma, Gliosarcoma

Neuroblastoma

Neuroblastoma, Ganglioneuroblastoma

Triple Negative Breast Neoplasms

Ganglioneuroblastoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Neuroblastoma

Hematologic Diseases, Multiple Myeloma

Breast Neoplasms

Carcinoma, Intraductal, Noninfiltrating

Carcinoma, Non-Small-Cell Lung, Neoplasms

Osteosarcoma

Neuroblastoma, Ganglioneuroblastoma

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Lymphoma, Follicular

Melanoma, Neoplasm Metastasis

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Lung Neoplasms, Neoplasm Metastasis

Prostatic Neoplasms

Lymphoma, Non-Hodgkin

Lymphoma, Lymphoma, Follicular

Prostatic Neoplasms

Neoplasm Metastasis, Sarcoma, Osteosarcoma

Brain Neoplasms, Medulloblastoma, Central Nervous System Neoplasms

Lymphoma, Lymphoma, T-Cell

Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Clinical Trials

Testing the SurVaxM Vaccine for Lung Cancer Prevention

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

LUNGVAC

Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

Lymvac-2

GIPI

Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer

GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

Rituximab and GM-CSF in Treating Patients With Newly Diagnosed Follicular B-Cell Lymphoma

Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer

Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma

Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma

Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas